Dashboard
Manage Tickers

KMPHZevra Therapeutics Inc


$ 4.80 $ 0.06 (1.26 %)    

Friday, 03-May-2024 15:57:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 4.81
$ 4.95
$ 0.00 x 0
$ 0.00 x 0
$ 4.79 - $ 4.95
$ 3.89 - $ 7.28
169,547
na
na
$ 3.39
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Zevra Therapeutics Begins Trading As ZVRA;...
03/01/2023 13:25:08

Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" sta...

zevra-therapeutics-says-arimoclomol-research-featured-in-two-poster-presentations-at-19th-annual-worldsymposium-2023
Zevra Therapeutics Says Arimoclomol Resear...
02/24/2023 12:36:49

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-ter...

kempharm-changes-name-to-zevra-therapeutics-inc-to-trade-on-nasdaq-under-new-ticker-symbol-zvra-starting-march-1-2023
KemPharm Changes Name To Zevra Therapeutic...
02/22/2023 12:41:12

kempharm-ceo-issued-letter-to-shareholders
KemPharm CEO Issued Letter to Shareholders
01/24/2023 12:36:05

KemPharm, Inc. (NasdaqGS: KMPH) today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Lett...

kempharm-announces-matthew-r-plooster-named-chairman-of-the-board-of-directors-and-richard-w-pascoe-appointed-chief-executive-officer
KemPharm Announces Matthew R. Plooster Nam...
01/09/2023 11:42:55

kempharm-announces-initiation-of-phase-2-clinical-trial-investigating-kp1077-for-treatment-of-idiopathic-hypersomnia
KemPharm Announces Initiation Of Phase 2 C...
12/21/2022 12:35:19

this-rare-disease-focused-stock-pipeline-is-underappreciated-analyst-initiating-coverage-says
This Rare Disease Focused Stock Pipeline I...
11/17/2022 19:05:48

kempharm-granted-us-fda-designated-orphan-approval-status-on-11172022-for-serdexmethylphenidate-for-the-treatment-of-idiopathic-hypersomnia-not-fda-approved-for-orphan-indication-sponsor
KemPharm Granted U.S. FDA Designated Orpha...
11/17/2022 17:55:10

benzingas-top-ratings-upgrades-downgrades-for-november-17-2022
Benzinga's Top Ratings Upgrades, Downgrade...
11/17/2022 15:13:36

Upgrades

cantor-fitzgerald-initiates-coverage-on-kempharm-with-overweight-rating-announces-price-target-of-20
Cantor Fitzgerald Initiates Coverage On Ke...
11/17/2022 11:17:56

Cantor Fitzgerald analyst Louis Chen initiates coverage on KemPharm (NASDAQ:KMPH) with a Overweight rating and announces Pri...

kempharm-q3-eps-019-misses-013-estimate-sales-287m-miss-320m-estimate
KemPharm Q3 EPS $(0.19) Misses $(0.13) Est...
11/09/2022 21:27:01

KemPharm (NASDAQ:KMPH) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.13) by...

earnings-scheduled-for-november-9-2022
Earnings Scheduled For November 9, 2022
11/09/2022 09:06:31

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on...

kempharms-earnings-a-preview
KemPharm's Earnings: A Preview
11/08/2022 18:21:10

KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors...

kempharms-lead-prodrug-shows-favorable-safety-profile-for-rare-sleeping-disorder
KemPharm's Lead Prodrug Shows Favorable Sa...
09/28/2022 16:07:20

kempharm-announces-topline-data-from-phase-1-clinical-trial-evaluating-cardiovascular-safety-of-serdexmethylphenidate
KemPharm Announces Topline Data From Phase...
09/28/2022 11:33:02

SDX administered at single doses of 80 mg and 200 mg was well-tolerated   CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -...

us-stocks-turn-lower-nasdaq-drops-over-100-points
US Stocks Turn Lower; Nasdaq Drops Over 10...
09/15/2022 16:04:09

U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.

benzingas-top-ratings-upgrades-downgrades-for-september-15-2022
Benzinga's Top Ratings Upgrades, Downgrade...
09/15/2022 14:16:42

Upgrades

canaccord-genuity-initiates-coverage-on-kempharm-with-buy-rating-announces-price-target-of-20
Canaccord Genuity Initiates Coverage On Ke...
09/15/2022 10:39:29

Canaccord Genuity analyst Sumant Kulkarni initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price...

apple-to-220-here-are-5-other-price-target-changes-for-wednesday
Apple To $220? Here Are 5 Other Price Targ...
08/17/2022 11:15:18

Wedbush raised the price target on Apple Inc. (NASDAQ: AAPL) from $200 to $220. However, Wedbush analyst Daniel Ives maintai...

hc-wainwright--co-maintains-buy-on-kempharm-lowers-price-target-to-10
HC Wainwright & Co. Maintains Buy on KemPh...
08/17/2022 10:38:44

HC Wainwright & Co. analyst Oren Livnat maintains KemPharm (NASDAQ:KMPH) with a Buy and lowers the price target from $11...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION